英文摘要 |
This paper aims to analyze new drug development projects of the Taiwanesebiotechnology companies from the perspective of open innovation. Taiwanesebiotechnology companies, such as Medigen Biotechnology Company and Panion &BF Biotechnology Company, transfer the foreign technologies and conduct thepreclinical trials and clinical trials, and make a profit after licensing out thetechnologies. This study investigates how Medigen which has rich internalresources leverages external resources to develop the new drug, and how Panion & BF which has less internal resources leverages huge external resources to developthe new drug. Two important issues are addressed in this study: how Taiwanesebiotechnology companies can leverage external resources and eventually make aprofit by licensing out technologies to international pharmaceutical companies; andhow Taiwanese biotechnology companies re-position themselves in the globalvalue chain of biotechnology industry. Research results indicate that although bothcompanies concentrate on the niche markets in Asia, they focus on differentproduct markets, with Medigen focusing on liver cancer drug market and Panion &BF focusing on kidney disease one. Additionally, both companies adopt openinnovation as a main business model, but they leverage external resources andnetwork in different ways. Medigen successfully licenses out to a foreignpharmaceutical company after clinical trials by relying on the network of its CEOas a medical doctor and by forming international joint development team for itsclinical trials. In contrast, Panion & BF successfully licenses out to an internationalpharmaceutical company by relying on outsourcing contract clinical/ researchorganization (CRO) through its networks in North America. |